Targeted therapy of atherosclerosis by pH-sensitive hyaluronic acid nanoparticles co-delivering all-trans retinal and rapamycin

Cheraga, Nihad; Zheng, Yi; Xu, Mingjie; Zou, Lin; Sun, Ning-Cong; Yue, Hang; Shan, Congjia; Yang, Zhongzhou; Chen, Lijuan; Huang, Ning‐Ping

doi:10.1039/d1nr06514a

Cited by 19 publications

(9 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cheraga et al constructed pH-sensitive nanoparticles (HR RAP NPs) to co-deliver all-trans retinal (ATR) and rapamycin (RAP). [130] HA was connected to antioxidants using a pH-sensitive hydrazone bond and further loaded with RAP. After 48 h and at pH 7.4, the release rate of ATR was < 10%.…”

Section: Ph-responsive Strategiesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Xiao,

Li,

Xiong

et al. 2023

Advanced Science

View full text Add to dashboard Cite

Atherosclerosis, the leading cause of death worldwide, is responsible for ≈17.6 million deaths globally each year. Most therapeutic drugs for atherosclerosis have low delivery efficiencies and significant side effects, and this has hampered the development of effective treatment strategies. Diversified nanomaterials can improve drug properties and are considered to be key for the development of improved treatment strategies for atherosclerosis. The pathological mechanisms underlying atherosclerosis is summarized, rationally designed nanoparticle‐mediated therapeutic strategies, and potential future therapeutic targets for nanodelivery. The content of this study reveals the potential and challenges of nanoparticle use for the treatment of atherosclerosis and highlights new effective design ideas.

show abstract

Section: Ph-responsive Strategiesmentioning

confidence: 99%

mentioning

confidence: 99%

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Xiao,

Li,

Xiong

et al. 2023

Advanced Science

View full text Add to dashboard Cite

show abstract

“…Rapamycin is an inhibitor of the mTOR signaling pathway. By applying advanced technology that makes Rapamycin target atherosclerotic plaques in experimental animals, a reduction in inflammation and lipid load and a shrinking of plaques was also observed in animal models, further suggesting that reduced mTOR signaling pathway activity can promote atheroprotective changes in AS (Huang et al, 2022a;Cheraga et al, 2022;Guo et al, 2022).…”

Section: Introductionmentioning

confidence: 95%

Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: A review

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Atherosclerosis (AS) is a chronic inflammatory disease that is a major cause of cardiovascular diseases (CVDs), including coronary artery disease, hypertension, myocardial infarction, and heart failure. Hence, the mechanisms of AS are still being explored. A growing compendium of evidence supports that the activity of the mechanistic/mammalian target of rapamycin (mTOR) is highly correlated with the risk of AS. The mTOR signaling pathway contributes to AS progression by regulating autophagy, cell senescence, immune response, and lipid metabolism. Various botanical drugs and their functional compounds have been found to exert anti- AS effects by modulating the activity of the mTOR signaling pathway. In this review, we summarize the pathogenesis of AS based on the mTOR signaling pathway from the aspects of immune response, autophagy, cell senescence, and lipid metabolism, and comb the recent advances in natural compounds from botanical drugs to inhibit the mTOR signaling pathway and delay AS development. This review will provide a new perspective on the mechanisms and precision treatments of AS.

show abstract

“…Based on these facts, we constructed a nanosized device bilirubin and V9302, a specific inhibitor of ASCT2, for psoriatic treatment. It was well-known that nanodelivery systems could enhance the drug performance by increasing solubility, improving stability, and facilitating drug delivery efficiency, and this strategy has been used in the treatment of many diseases, including ulcerative colitis, [20][21][22] arthritis, [23][24][25] atherosclerosis, [26][27][28] cancers, [29][30][31] as well as psoriasis. [32][33][34] The prepared bilirubin/V9302 nanoparticles (BVn) here could maintain certain drug ratio and stability, enhance drug delivery efficiency, and reverse symptoms and histologic changes in an imiquimod (IMQ)induced psoriasis mouse model (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

Glutamine‐Based Metabolism Normalization and Oxidative Stress Alleviation by Self‐Assembled Bilirubin/V9302 Nanoparticles for Psoriasis Treatment

Jiang

Huang

Cai

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Psoriasis is an immune-mediated chronic inflammatory skin disorder characterized by epidermal hyperplasia and infiltration of inflammatory cells. Even though the pathogenesis remains unclear, T helper 17 (Th17) cells-mediated inflammation and keratinocyte-involved proliferation are considered to play key roles during the occurrence and the development of psoriasis. Therefore, suppressing the infiltration/function of Th17 and the abnormal hyperplasia of keratinocytes can be a rational strategy for ameliorating and treating psoriasis. In this study, a self-assembly nanoparticle (BVn) is developed with bilirubin (an endogenous antioxidant) and V9302 (a blocker of ASCT2, an amino acid transporter mediating glutamine influx for providing energy and activating mammalian target of rapamycin [mTOR] pathway) to intervene the local metabolism and alleviate oxidative stress for psoriasis treatment. BVn effectively suppresses inflammatory keratinocyte proliferation and scavenges excess reactive oxygen species (ROS). In the in vivo psoriasis mouse model, BVn shows increased permeation and delayed retention in the psoriatic lesion and reverses the psoriasis-related symptoms, evidenced by the normalized keratinocyte condition and decreased Th17 infiltration/activation. Mechanism study indicates that BVn not only cut off the energy supply but also suppressed cell proliferation or lymph cell expansion by deactivating mTOR pathway, besides alleviated oxidative stress. BVn-based glutamine metabolism modulation strategy offers a promising strategy for psoriasis therapy.

show abstract

Targeted therapy of atherosclerosis by pH-sensitive hyaluronic acid nanoparticles co-delivering all-trans retinal and rapamycin

Abstract: Atherosclerosis, the leading cause of death in the elderly worldwide, is typically characterized by elevated reactive oxygen species (ROS) levels and chronic inflammatory state at the arterial plaques. Herein, pH-sensitive...

Cited by 19 publications

References 77 publications

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Recent Advances in Anti‐Atherosclerosis and Potential Therapeutic Targets for Nanomaterial‐Derived Drug Formulations

Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: A review

Glutamine‐Based Metabolism Normalization and Oxidative Stress Alleviation by Self‐Assembled Bilirubin/V9302 Nanoparticles for Psoriasis Treatment

Contact Info

Product

Resources

About